N

    Neuroone Medical Technologies Corp (NMTC)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.70
    -0.07 (-3.95%)

    Market Cap: $15.48M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(15/21)
    Avg Surprise
    +13.66%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.46 - $0.09
    3 analysts
    Revenue Consensus
    $2M
    Range$2M - $2M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.22 - $-0.14
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.14+15.7%
    60d ago$-0.14+15.7%
    30d ago$-0.15+13.7%
    7d ago$-0.15+13.7%
    Current$-0.17
    Revenue Consensus
    $3M
    Range$3M - $4M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.17---
    Sep 26EST
    		-$-0.26---
    Jun 26
    Reported Aug 13
    		$-0.28$-0.22-27.27%Miss-55.6%
    Mar 26
    Reported May 12
    		$-0.25$-0.23-8.43%Miss+41.5%
    Dec 25
    Reported Feb 17
    		$-0.18$-0.24+25.00%Beat-150.0%
    Sep 25
    Reported Dec 17
    		$-0.03$-0.06+46.00%Beat+71.1%
    Jun 25
    Reported Aug 14
    		$-0.18$-0.30+40.00%Beat-77.9%
    Mar 25
    Reported May 13
    		$-0.42$-0.54+22.22%Beat-281.1%
    Dec 24
    Reported Feb 12
    		$0.36$-0.60+160.00%Beat+142.9%
    Sep 24
    Reported Dec 17
    		$-0.11$-0.09-24.44%Miss+13.8%
    Jun 24
    Reported Aug 14
    		$-0.10$-0.09-12.44%Miss+91.6%
    Mar 24
    Reported May 14
    		$-0.11$-0.10-10.20%Miss+91.3%
    Dec 23
    Reported Feb 13
    		$-0.84$-0.84+0.00%Beat-27.3%
    Sep 23
    Reported Dec 14
    		$-0.13$-0.17+23.53%Beat-44.4%
    Jun 23
    Reported Aug 14
    		$-1.20$-1.23+2.44%Beat-17.6%
    Mar 23
    Reported May 11
    		$-1.26$-1.23-2.44%Miss-10.5%
    Dec 22
    Reported Feb 13
    		$-0.66$-0.66+0.00%Beat+38.9%
    Sep 22
    Reported Dec 22
    		$-0.09$-0.11+18.18%Beat+59.1%
    Jun 22
    Reported Aug 11
    		$-1.02$-1.35+24.44%Beat-308.0%
    Mar 22
    Reported May 12
    		$-1.14$-1.20+5.00%Beat-78.1%
    Dec 21
    Reported Feb 14
    		$-1.08$-1.14+5.26%Beat-1100.0%
    Sep 21
    Reported Dec 15
    		$-0.22$-0.22+0.00%Beat-633.3%
    Jun 21
    Reported Aug 13
    		$-0.25$-0.25+0.00%Beat+43.2%
    Mar 21
    Reported May 14
    		$-0.64N/AN/ABeat-540.0%
    Dec 20
    Reported Feb 16
    		$-0.09N/AN/ABeat+73.5%
    Sep 20
    Reported Dec 8
    		$-0.03N/AN/ABeat+70.0%
    Jun 20
    Reported Aug 13
    		$-0.44$0.00N/AMiss-214.3%
    Mar 20
    Reported May 14
    		$-0.10N/AN/ABeat+50.0%
    Dec 19
    Reported Jan 28
    		$-0.34N/AN/ABeat-142.9%
    Sep 19
    Reported Dec 20
    		$-0.10N/AN/ABeat+60.0%
    Jun 19
    Reported Aug 14
    		$-0.14N/AN/ABeat+12.5%
    Mar 19
    Reported May 10
    		$-0.20N/AN/ABeat-17.6%
    Dec 18
    Reported Feb 14
    		$-0.14N/AN/ABeat+72.9%
    Sep 18
    Reported Dec 12
    		$-0.25N/AN/ABeat+60.1%
    Jun 18
    Reported Aug 13
    		$-0.16N/AN/ABeat+71.5%
    Mar 18
    Reported Apr 16
    		$-0.17N/AN/ABeat+74.3%
    Dec 17
    Reported Mar 31
    		$-0.52N/AN/ABeat-23.3%
    Sep 17
    Reported Nov 14
    		$-0.63N/AN/ABeat-335.9%
    Jun 17
    Reported Aug 14
    		$-0.56$0.00N/AMiss-
    Mar 17
    Reported Apr 17
    		$-0.66$0.00N/AMiss-
    Dec 16
    Reported Mar 31
    		$-0.42$0.00N/AMiss-
    Sep 16
    Reported Nov 21
    		$-0.14$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.30EV/EBITDA-2.10x
    Price/FCF-2.07xFCF Yield-48.20%
    Profitability
    Profit Margin-59.70%Operating Margin-122.90%
    ROE-124.70%ROIC-147.05%
    Financial Health
    Debt/Equity0.02xInterest CoverageN/A
    Current Ratio2.84xQuick Ratio1.71x
    Trading Statistics
    Beta0.64Avg Volume766.09K
    52-Week High$6.9652-Week Low$1.42

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.00
    SMA 20$1.84
    SMA 50$2.25
    SMA 200$3.88
    EMA 10$1.91
    EMA 20$1.93
    EMA 50$2.29
    EMA 200$3.59

    MACD

    Line: -0.07Signal: -0.09Hist: 0.02

    ADX

    ADX: 29.2+DI: 37.1-DI: 17.4

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down36.0
    PSAR$3.45

    Bollinger Bands

    Upper Band$2.29
    Lower Band$1.40
    %B Position4851%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    38.6

    Momentum Oscillators

    Stoch %K17.6
    Stoch %D35.4
    Williams %R-88.2
    ROC (10d)-9.6%
    Momentum-0.18
    CCI (20d)-53.0
    MFI (14d)95.7

    Volatility Measures

    ATR (14d)$0.32(18.6%)
    StdDev (20d)0.22
    Hist Vol119.8%(High)

    Volume Flow

    VWAP$1.71
    OBV-8.1M
    AD Line9.7B
    CMF (20d)-0.787

    Volume Metrics

    Avg Vol (20d)803.2K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.95

    Pivot Points

    R3$2.18
    R2$2.07
    R1$1.92
    Pivot Point$1.81
    S1$1.66
    S2$1.55
    S3$1.40

    Advanced Oscillators

    TSI-10.34
    Ultimate Osc25.0
    KST-19.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.97M$2.39M$2.89M$2.74M$1.70M$1.39M$3.27M$272,284$825,776$1.38M$977,649$741,780
    Cost of Revenue$790,496$1.10M$1.32M$1.21M$781,215$615,489$1.35M$131,222$543,904$986,875$711,335$548,125
    Gross Profit$1.18M$1.29M$1.57M$1.53M$914,835$771,061$1.93M$141,062$281,872$390,419$266,314$193,655
    Operating Expenses$3.61M$3.39M$3.28M$2.90M$2.80M$3.45M$215,682$2.96M$3.08M$3.28M$3.66M$3.36M
    R&D$1.43M$1.47M$1.39M$1.12M$1.18M$1.51M$1.17M$1.11M$1.19M$1.27M$1.48M$1.78M
    SG&A$2.18M$1.92M$1.89M$1.78M$1.57M$1.94M$2.00M$1.95M$1.84M$1.99M$2.12M$1.56M
    Operating Income$-2,424,312$-2,100,844$-1,707,307$-1,371,064$-1,886,600$-2,680,016$1.71M$-2,816,735$-2,793,901$-2,886,100$-3,390,480$-3,164,744
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$334,063$9,325$0$324,738$228,988$0$0$0$0
    Income Before Tax$-2,006,331$-2,085,669$-1,437,890$-1,619,221$-1,500,868$-2,270,607$1.79M$-3,350,595$-2,767,525$-2,855,090$-3,344,900$-3,135,121
    Income Tax Expense$0$0$0$0$0$0$1.79M$0$3$0$3$18,697
    Net Income$-2,006,331$-2,085,669$-1,437,890$-1,619,221$-1,500,868$-2,270,607$1.79M$-3,350,595$-2,767,525$-2,855,090$-3,344,900$-3,135,121
    EBITDA$-1,959,331$-2,025,640$-1,372,367$-1,554,901$-1,424,949$-2,204,973$2.18M$-2,954,521$-2,704,418$-2,794,190$-3,286,243$-3,072,613
    EBIT$-2,006,331$-2,085,669$-1,437,890$-1,619,225$-1,491,543$-2,270,607$2.11M$-3,018,648$-2,767,525$-2,855,090$-3,344,900$-3,135,121
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NMTC

    News

    NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% But Supply Chain Constraints Force Guidance Cut

    NeuroOne Medical Technologies Corp (NMTC) reported a 16% increase in Q3 fiscal 2026 product revenue and strong order growth, with significant gross margin expansion. Despite positive developments like ISO 13485 certification and progress in drug delivery platforms, the company faced significant manufacturing and supply chain constraints, leading to a widened net loss and a reduction in fiscal year 2026 revenue guidance. The CEO highlighted ongoing efforts to mitigate these issues, including qualifying a second manufacturing site and exploring alternative commercialization strategies for certain product lines.

    GuruFocus•8/17/26•
    Neutral

    Earnings call transcript: NeuroOne Medical posts Q3 2026 revenue growth as shares fall

    NeuroOne Medical Technologies reported a 16% year-over-year increase in Q3 2026 product revenue, reaching $2.0 million, driven by stronger sales of its OneRF brain ablation products and a 43% jump in orders. Despite revenue growth and improved gross margins, the company's net loss widened to $2.0 million, and its shares fell, trading near their 52-week low. Management highlighted recent ISO 13485 certification as a key step for international expansion and discussed progress on new product lines, including the StereoCED drug delivery platform and the BVNA system for back pain.

    Investing.com•8/13/26•
    Neutral

    NeuroOne Medical Technologies (NASDAQ: NMTC) posts larger loss and flags going concern risk

    NeuroOne Medical Technologies (NMTC) reported a deeper net loss of $2.01 million for Q3 2026 and $5.83 million for the nine months ended June 30, 2026, significantly larger than the previous year. The company's cash and cash equivalents dwindled to $2.05 million, leading management to express substantial doubt about its ability to continue as a going concern, with current funds expected to last only until January 2027. Despite an increase in product revenue, the absence of recurring license revenue and higher operating expenses contributed to the rising losses and increased cash burn, further complicated by high customer concentration and ongoing dilution risk from equity financing.

    Stock Titan•8/13/26•
    Bearish

    NeuroOne posts Q3 FY2026 revenue up 16% to $2.0M; gross margin expands to 59.9%

    NeuroOne (NMTC) reported a 16% increase in Q3 FY2026 product revenue to $1.97 million, with product gross margin expanding to 59.9%. Despite a net loss of $2.01 million, the company secured $2.7 million in new product orders and achieved ISO 13485:2016 certification. Significant progress was also made on the StereoCED drug delivery platform and clinical research collaborations.

    TradingView•8/13/26•
    Bullish

    Form 8K Neuroone Medical Technologies Corp For: 13 August By Investing.com

    This article announces that Neuroone Medical Technologies Corp filed a Form 8K on August 13. It includes the company's stock symbol (NMTC) and its current performance. The content primarily serves as a placeholder for the filing and does not provide further details about the Form 8K's contents.

    Investing.com India•8/13/26•
    Neutral

    Frequently Asked Questions About NMTC

    Does NMTC pay dividends?
    Neuroone Medical Technologies Corp (NMTC) does not currently pay a regular dividend.
    What is NMTC's market cap?
    Neuroone Medical Technologies Corp (NMTC) has a market capitalization of $15.48M with a current stock price of $1.70.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In